三个第三阶段随机试验中的心脏事件,包括慢性淋巴细胞白血病中的阿卡拉布鲁替尼
Rupal O'Quinn1, Anthony J Corry2, Naghmana Bajwa2
1Perelman School of Medicine and The Leonard Davis Institute of Health Economics at the University of Pennsylvania, Penn Presbyterian Medical Center, Philadelphia, PA.
Clinical lymphoma, myeloma & leukemia
|May 24, 2025
概括
第二代布鲁顿氨酸激酶 (BTK) 抑制剂阿卡拉布鲁丁尼 (Acalabrutinib) 在CLL患者中显示较低的心脏事件率,与其他BTK抑制剂相比. 这种改善的心脏安全概况适用于患有或没有先前存在的心血管疾病的患者.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- 第一代布鲁顿氨酸激酶 (BTK) 抑制剂易布鲁替尼对慢性淋巴细胞白血病 (CLL) 有效,但具有显著的心脏风险.
- 第二代BTK抑制剂acalabrutinib提供了比ibrutinib更好的选择性和潜在的更好的心血管安全概况,心房动事件较少.
- 需要全面分析与活性比较剂相比,与acalabrutinib相关的心脏结果,特别是在具有和没有基线心血管疾病的患者中.
研究的目的:
- 对接受acalabrutinib治疗的患者与包括ibrutinib在内的活性比较剂进行心脏结果的综合分析.
- 为了评估患有或没有基线心血管疾病的患者心脏事件的发生率.
- 为了比较acalabrutinib在3期试验中的不同治疗臂中关于心脏疾病的安全概况.
主要方法:
- 分析了三项临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床临床
- 对心脏疾病事件的暴露调整发病率 (EAIR;事件/100人/月) 的计算.
- 根据基线心血管疾病的存在对分析进行分层;所有分析都是描述性的,没有统计比较.
主要成果:
- 总共有1362名患者被纳入,其中404名 (29.7%) 患有至少一种基线心血管疾病.
- 与所有试验中的活跃对比剂相比,acalabrutinib在任何级别的心脏疾病事件的整体EAIR都较低.
- 在患有基线心血管疾病的患者中,acalabrutinib没有增加心脏事件,并且与活跃对比剂相比,de novo心脏事件的EAIR也较低.
结论:
- 与活性比较剂相比,acalabrutinib治疗心脏疾病事件的发生率总体上相对较低.
- 在CLL患者中,acalabrutinib表现出良好的心脏安全概况,而不考虑基线心血管疾病的存在.
- 这些发现支持acalabrutinib作为在CLL治疗中对心脏毒性的潜在更安全选择.
相关概念视频
01:11Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:16Clinical Trials
10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.2K
01:30Acute Coronary Syndrome III: Diagnostic Studies
219
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
219